FDC vs MARKSANS: Stock Comparison

FDC Limited vs Marksans Pharma Limited

Live data: 22 July 2026, 2:59 PM IST • Source: NSE and company filings

Marksans Pharma Limited is the larger company by market capitalisation. FDC Limited shows a lower P/E, a higher dividend yield and lower leverage, while Marksans Pharma Limited shows a higher ROE, faster revenue growth and a higher ROCE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of FDC Limited and Marksans Pharma Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, FDC is more favourable on 7 of 13 scored metrics and MARKSANS on 6These counts are context-free and are not an overall rating.

Key Differences

Market Cap
MARKSANS is the larger company
₹10,928 Cr vs ₹6,713 Cr
P/E Ratio
FDC has a lower P/E
23.94x vs 28.31x
P/B Ratio
FDC has a lower P/B
2.71x vs 3.91x
EPS
FDC has higher earnings per share
₹17.3 vs ₹9.71
Dividend Yield
FDC has a higher dividend yield
2.39% vs 0.29%
Revenue Growth (TTM YoY)
MARKSANS has faster revenue growth
20.8% vs 18.9%
EPS Growth (TTM YoY)
FDC has faster EPS growth
166.8% vs 63.5%
Qtr Sales Growth
MARKSANS has stronger quarterly sales growth
20.8% vs 18.9%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricFDCMARKSANS
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricFDCMARKSANS
Live Price₹411.75₹241.1
Day Change-0.36%-7.38%
Volume1.33 L37.45 L
52-Week High₹527.8₹281.6
52-Week Low₹312.95₹155
Distance from 52W High-21.99%-14.38%

Valuation

MetricFDCMARKSANS
Market Cap₹6,713 Cr₹10,928 Cr
P/E Ratio23.94x28.31x
P/B Ratio2.71x3.91x
EPS₹17.3₹9.71
Book Value₹152.62₹66.74
Dividend Yield2.39%0.29%

Growth

MetricFDCMARKSANS
Revenue Growth (TTM YoY)18.9%20.8%
EPS Growth (TTM YoY)166.8%63.5%
Qtr Sales Growth18.9%20.8%
Qtr Profit Growth167%63.6%

Profitability & Leverage

MetricFDCMARKSANS
ROE12.5%15.2%
ROCE16.7%18.8%
Net Margin12.96%14.16%
Operating Margin15.9%20.4%
Debt to Equity0.01x0.11x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricFDCMARKSANS
Promoter Holding69.66%43.87%
FII Holding1.4% 1 pp16.76% 8.64 pp
DII Holding6.31% 0.02 pp6.57% 0.66 pp
Public Holding22.63% 0.98 pp32.79% 9.3 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: FDC Limited and Marksans Pharma Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.